Liposomes Patents (Class 424/450)
-
Patent number: 11045419Abstract: The disclosure provides methods for preparation of carbohydrate replacement therapies (CRT) that include nanocarriers of carbohydrates and glycolipids for pharmaceutical delivery to cell interior, endoplasmic reticulum, and Golgi for treating CDG type I and CDG type II diseases as well as other metabolic disorders.Type: GrantFiled: September 11, 2019Date of Patent: June 29, 2021Assignee: Glycomine, Inc.Inventors: Agnes Rafalko, Tatyana Chernenko
-
Patent number: 11033625Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.Type: GrantFiled: October 15, 2020Date of Patent: June 15, 2021Assignee: Allergan, Inc.Inventor: Terrence J. Hunt
-
Patent number: 11028148Abstract: This disclosure provides non-naturally occurring collagen and elastin molecules. The non-naturally occurring collagens and elastins include truncated collagens, truncated elastins, as well as fusion proteins thereof. The non-naturally occurring collagen and elastin are useful in foods, cosmetics and many other products and uses.Type: GrantFiled: April 2, 2020Date of Patent: June 8, 2021Assignee: GELTOR, INC.Inventors: Nikolay Ouzounov, Alexander Lorestani, Monica Bhatia
-
Patent number: 11027025Abstract: The present invention relates to compositions comprising and methods of using synthetic polynucleotides, e.g., modified mRNA, encoding CRISPR related proteins including dCAS9 and synthetic sgRNAs targeting a gene of interest.Type: GrantFiled: July 11, 2014Date of Patent: June 8, 2021Assignee: ModernaTX, Inc.Inventors: Stephen G. Hoge, Eric Yi-Chun Huang, Tirtha Chakraborty
-
Patent number: 11026902Abstract: The described invention provides a topical delivery system comprising a pharmaceutical composition for application directly to a skin of a subject in need thereof comprising (a) an effective therapeutic amount of an active therapeutic agent; (b) chemical drivers comprising an amino benzoate local anesthetic, ethoxydiglycol and methylsulfonylmethane (MSM) that in combination are effective to synergistically deliver the therapeutic agent; and (c) a depot component for keeping the pharmaceutical composition in the skin. Methods for delivering an active therapeutic agent into skin, for keeping it in the skin, for reducing systemic side effects attributable to entry of the active agent into the blood stream, and a method for treating a condition, disease or disorder of skin topically also are described in accordance with the embodiments of the described invention.Type: GrantFiled: March 4, 2019Date of Patent: June 8, 2021Assignee: SAMBRIA PHARMACEUTICALS, LLCInventor: Michael Harvey Greenspan
-
Patent number: 11026941Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.Type: GrantFiled: August 14, 2019Date of Patent: June 8, 2021Assignee: GRIFOLS, S.A.Inventors: David C. Cipolla, James Blanchard
-
Patent number: 11020337Abstract: The invention provides a cosmetic composition for skin and/or hair care comprising one or more ?-aspartyl dipeptides, or oligomers thereof, or salts thereof, wherein each of said ?-aspartyl dipeptides comprises a ?-L-aspartyl moiety as the first amino acid residue. The invention further relates to a method for human skin and/or hair care, including anti-aging and/or anti-hair loss utilizing this composition.Type: GrantFiled: March 24, 2017Date of Patent: June 1, 2021Assignee: Cysal GmbHInventors: Ahmed Sallam, Martin Krehenbrink, Dimitar Kalkandzhiev
-
Patent number: 11013812Abstract: The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid. In some embodiments, the present invention provides compositions and methods in which the lipid nanoparticles further comprise helper lipids and PEG-modified lipids. The resulting formulation comprises a high encapsulation percentage for nucleic acids.Type: GrantFiled: October 11, 2019Date of Patent: May 25, 2021Assignee: TRANSLATE BIO, INC.Inventors: Frank DeRosa, Michael Heartlein, Shrirang Karve
-
Patent number: 11007256Abstract: Single molecules useful in vaccine compositions, and methods of making and using the same, are described.Type: GrantFiled: September 26, 2017Date of Patent: May 18, 2021Assignee: The University of ToledoInventors: Abhishek R. Vartak, Steven J. Sucheck, Katherine Ann Wall, Anthony Quinn, Marcia F. Mcinerney
-
Patent number: 11007284Abstract: Acoustically responsive stabilized microbubbles formulated with a phospholipid monolayer shell, an encapsulated bioactive gas, and an encapsulated perfluorocarbon gas of the formula CxFy in a volume ratio of from about 10:1 to about 1:10, wherein X is greater than or equal to 3, are disclosed. Also provided are methods for promoting localized vasodilation in a patient in need thereof by delivering a microbubble comprising a phospholipid monolayer shell and an encapsulated bioactive gas locally to a target diseased section of the patient's vasculature; and releasing the bioactive gas at the target diseased section, wherein the microbubble comprises the bioactive gas in a ratio of from about 10:1 to about 1:10 by volume with a perfluorocarbon gas.Type: GrantFiled: September 3, 2019Date of Patent: May 18, 2021Assignee: University of CincinnatiInventors: Christy Holland, Himanshu Shekhar, Arunkumar Palaniappan
-
Patent number: 11000599Abstract: A polypeptide conjugate for use in a method for binding and/or internalization of the polypeptide conjugate to a mammalian cell having a transferrin receptor (TFRC) and/or receptor for advanced glycation end products (RAGE). The polypeptide conjugate may be used in a method for targeting of a drug delivery system or diagnostic delivery system.Type: GrantFiled: May 29, 2018Date of Patent: May 11, 2021Assignee: S. M. Discovery Group Inc.Inventors: Seyed Moien Moghimi, Linping Wu, Davoud Ahmadvand, Ladan Parhamifar
-
Patent number: 11000477Abstract: To provide a preparing method for a charged niosome which is formed of a lipid containing a diacylglycerol PEG adduct and which is capable of being excellently impregnated into the skin and stored in the skin.Type: GrantFiled: July 20, 2018Date of Patent: May 11, 2021Assignee: J-NETWORK, INC.Inventors: Tatsuro Miyoshi, Brian Charles Keller, Akira Kodama
-
Patent number: 11000478Abstract: Provided herein is technology relating to incorporation of drugs into liposomes and particularly, but not exclusively, to methods for incorporating drugs into liposomes using a weak base and related compositions.Type: GrantFiled: March 14, 2018Date of Patent: May 11, 2021Assignee: COMFORT CARE FOR ANIMALS LLCInventors: Timothy D. Heath, Lisa Ann Krugner-Higby, Amy Lautenbach
-
Patent number: 10994017Abstract: Described herein are methods and compositions for nerve delivery molecules that carry imaging cargo or therapeutic cargo to the neurons or nerves.Type: GrantFiled: December 1, 2017Date of Patent: May 4, 2021Assignee: Avelas Biosciences, Inc.Inventors: Jesus Gonzalez, Junjie Liu, Marcel Miampamba
-
Patent number: 10993914Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: GrantFiled: September 11, 2019Date of Patent: May 4, 2021Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Patent number: 10980869Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: GrantFiled: September 13, 2017Date of Patent: April 20, 2021Assignee: Baylor Research InstituteInventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
-
Patent number: 10980840Abstract: The present disclosure provides novel methods for increasing ?-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase ?-cell viability.Type: GrantFiled: May 23, 2018Date of Patent: April 20, 2021Assignee: CITY OF HOPEInventors: Sanjay Awasthi, Sushma Yadav, Ismail Al Abdullah, Fouad Kandeel, Brian McFadden, Indu Nair, Sharad S. Singhal
-
Patent number: 10982210Abstract: The invention provides compositions for delivery of cargo to cells. The invention also provides compositions that bind multiple agents simultaneously. The compositions are useful as therapeutics. Methods of using the compositions are also provided.Type: GrantFiled: March 1, 2019Date of Patent: April 20, 2021Assignee: Sixfold Bioscience Ltd.Inventors: George Foot, Anna Perdrix Rosell, Zuzanna Brzosko
-
Patent number: 10980798Abstract: Provide is a method of using a topoisomerase I inhibitor in treatment of cancer to reduce bone marrow suppression. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition. The composition has at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof, and at least one polyethylene glycol (PEG) conjugated phospholipid, wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.45:1 to about 1.05:1.Type: GrantFiled: July 3, 2019Date of Patent: April 20, 2021Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.Inventors: Pei Kan, ChiaHung Hung, Keelung Hong, Yun-Long Tseng, Yung-Hsu Chan
-
Patent number: 10973753Abstract: The invention relates to a dispersion of polymer particles stabilized with a stabilizer in a nonaqueous medium containing at least one hydrocarbon-based oil, the polymer of the particles being a C1-C4 alkyl (meth)acrylate polymer; the stabilizer being a C1-C4 alkyl (meth)acrylate polymer and optionally of a silicone macromonomer (I): the stabilizer being a polymer comprising from 50% to 100% by weight, relative to the total weight of the stabilizer, of C8-C22 alkyl acrylate, from 0 to 50% by weight of C1-C4 alkyl (meth)acrylate and optionally silicone macromonomer (I). The invention also relates to the composition comprising said dispersion of polymer particles. Cosmetic use for caring for and making up keratin materials.Type: GrantFiled: December 10, 2015Date of Patent: April 13, 2021Assignee: L'OREALInventors: Julien Portal, Xavier Schultze, Simon Taupin
-
Patent number: 10973761Abstract: The present invention relates to a formulation comprising a primary surfactant, a tocol phosphate, water, an active agent, and optionally an oil, wherein the active agent and/or the optional oil comprises a hydrophobic phase.Type: GrantFiled: December 9, 2016Date of Patent: April 13, 2021Assignee: Phosphagenics LimitedInventor: Mahmoud El-Tamimy
-
Patent number: 10973764Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.Type: GrantFiled: June 26, 2019Date of Patent: April 13, 2021Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Shao-Ling Huang, Melvin E. Klegerman, Yong-Jian Geng, Hyunggun Kim, David D. Mcpherson
-
Patent number: 10973935Abstract: A stabilized nanobubble can include a membrane that defines at least one internal void, which includes at least one gas. The membrane can include at least one lipid and at least one nonionic triblock copolymer that is effective to control the size of the nanobubble without compromising in vitro and in vivo echogenicity of the nanobubble.Type: GrantFiled: July 23, 2019Date of Patent: April 13, 2021Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Agata Exner, Tianyi Krupka, Luis Solorio
-
Patent number: 10975112Abstract: Cell binding agent-drug conjugates comprising hydrophilic linkers, and methods of using such linkers and conjugates are provided.Type: GrantFiled: June 16, 2015Date of Patent: April 13, 2021Assignee: HANGZHOU DAC BIOTECH CO., LTD.Inventor: Robert Yongxin Zhao
-
Patent number: 10968433Abstract: A method of generating one of podocyte progenitor cells and neural stem/progenitor cells comprising the steps of collecting a urine specimen from a patient; centrifuging the urine specimen; and removing the one of podocyte progenitor cells and neural stem/progenitor cells.Type: GrantFiled: December 21, 2018Date of Patent: April 6, 2021Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITYInventor: Yuping Wang
-
Patent number: 10959951Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.Type: GrantFiled: May 15, 2020Date of Patent: March 30, 2021Assignees: TAIWAN LIPOSOME CO., LTD., TLC BIOPHARMACEUTICALS, INC.Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
-
Patent number: 10961188Abstract: Disclosed herein is a compound of Formula I, wherein R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: December 10, 2019Date of Patent: March 30, 2021Assignee: Arcturus Therapeutics, Inc.Inventors: Joseph E. Payne, Padmanabh Chivukula, Priya Karmali, Steven P. Tanis
-
Patent number: 10961289Abstract: The present invention relates to small molecules interfering with the conformational space of the TONSL ARD occupied by the histone H4 tail. These small molecules targets the binding pocket of TONSL encompassing the H4 residues K12-R23 and act by preventing or disrupting the binding of the H4 tail K12-R23 with the TONSL ARD via direct competition or via allosteric disruption of the binding pocket.Type: GrantFiled: November 29, 2019Date of Patent: March 30, 2021Assignees: The University of Copenhagen, Memorial Sloan-Kettering Cancer CenterInventors: Anja Groth, Giulia Saredi, Hongda Huang, Colin Hammond, Dinshaw Patel
-
Patent number: 10952984Abstract: The present disclosure provides an all-trans retinoic acid injectable formulation and its application for a preparation of a pharmaceutical product for treating tumor. The all-trans retinoic acid injectable formulation includes all-trans retinoic acid and solubilizers. The apparent solubility of the all-trans retinoic acid is increased from 0.01 mg/mL to 0.1 mg/mL or more. The injectable formulation can reduce the activity of an infiltrated immuno-suppressive cell population within blood or tumor tissue of a cancer patient, and improve immune clearing effects against tumors. It can be applied independently or together with other pharmaceutical products to inhibit tumor growth and prevent tumor recurrence.Type: GrantFiled: August 17, 2017Date of Patent: March 23, 2021Assignee: HIGHFIELD BIOPHARMACEUTICAL CORPORATIONInventors: Yuhong Xu, Xiaolong Chen, Anjie Zheng, Lieyi Wu
-
Patent number: 10954282Abstract: This invention provides nucleic acid molecules encoding the N-terminal 158 amino acids of secreted human Fibroblast Growth Factor Binding Protein 3 (NBP158), pharmaceutical compositions comprising NBP158 polypeptide, and methods for treating metabolic disorders and conditions using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: GrantFiled: December 9, 2014Date of Patent: March 23, 2021Inventor: Wentao Zhang
-
Patent number: 10945953Abstract: Provided is a composition including a dispersion medium including: an aqueous solution; a first active ingredient; a flavor agent; and a first type of polymer; and a dispersed phase including: a population of particles, each particle including: a core including: a second active ingredient a second type of polymer; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a third type of polymer; a plurality of lipophilic carriers; and a third active ingredient; and a plurality of emulsifying agents.Type: GrantFiled: September 14, 2020Date of Patent: March 16, 2021Assignee: Nulixir Inc.Inventor: Ehsan Moaseri
-
Patent number: 10943350Abstract: A fully automated method for detecting and measuring a target of interest such as vasculature, capable of processing whole slide images and extracting large number of targets of interest per slide. The method includes the steps of: (a) obtaining a digital image of a tissue specimen; (b) using a first set of mathematical algorithms based on objectively-defined criteria to isolate the one or more targets of interest from the slide, thereby detecting the one or more targets of interest; and (c) using a second set of mathematical algorithms based on objectively-defined criteria to construct boundaries around the detected targets of interest and obtain quantitative attributes of these one or more targets throughout the slide, thereby measuring the one or more targets.Type: GrantFiled: February 25, 2016Date of Patent: March 9, 2021Assignee: LONDON HEALTH SCIENCE CENTER RESEARCH INC.Inventors: Aaron Devin Ward, Yi Wen Xu, John Geoffrey Pickering
-
Patent number: 10940111Abstract: A method of reducing a friction coefficient of a surface is disclosed herein, comprising attaching a water-soluble polymer to the surface, and contacting the water-soluble polymer with liposomes, thereby coating the surface with an amphiphilic lipid. Further disclosed herein are solutions comprising a water-soluble polymer attachable to the surface, liposomes, and an aqueous carrier, for reducing a friction coefficient of a surface, and methods utilizing same. Articles of manufacture comprising a substrate coated by a water-soluble polymer which is coated by an amphiphilic lipid are also described, as are uses and methods for treating a synovial joint disorder associated with increased articular friction.Type: GrantFiled: June 15, 2015Date of Patent: March 9, 2021Assignee: Yeda Research and Development Co. Ltd.Inventors: Jacob Klein, Ronit Goldberg, Jasmine Seror, Weifeng Lin, Reut Mashiach
-
Patent number: 10940207Abstract: The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid. In some embodiments, the present invention provides compositions and methods in which the lipid nanoparticles further comprise helper lipids and PEG-modified lipids. The resulting formulation comprises a high encapsulation percentage for nucleic acids.Type: GrantFiled: January 27, 2020Date of Patent: March 9, 2021Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Michael Heartlein, Shrirang Karve
-
Patent number: 10940209Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.Type: GrantFiled: July 5, 2018Date of Patent: March 9, 2021Assignee: Ăcole Polytechnique FĂ©dĂ©rale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, David Scott Wilson
-
Patent number: 10940193Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.Type: GrantFiled: January 18, 2019Date of Patent: March 9, 2021Assignee: THE TEXAS A&M UNIVERSITY SYSTEMInventors: Thomas A. Ficht, Allison Ficht, Renee Tsolis, Leslie Garry Adams, Angela M. Arenas-Gamboa
-
Patent number: 10933131Abstract: The present invention relates to compositions and methods for immunomodulation which are effective for increasing conception rate in cows.Type: GrantFiled: July 25, 2017Date of Patent: March 2, 2021Assignee: BAYER ANIMAL HEALTH GMBHInventors: Jason Nickell, Daniel Keil, Albert Abraham, Warren Tully, Richard Gerhardus Martinu Olde Riekerink, Terry Settje, Leland Vickers, Stuart Nibbelink
-
Patent number: 10933032Abstract: Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 formulations and chemotherapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemotherapeutic agents may be at least one of antimetabolites or anthracyclines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.Type: GrantFiled: April 8, 2014Date of Patent: March 2, 2021Assignee: Berg LLCInventors: Niven Rajin Narain, Rangaprasad Sarangarajan
-
Patent number: 10933027Abstract: The present invention relates to a construct including a porous core, a cargo, and a spacer disposed between the core and the cargo. In some examples, the construct further includes an outer layer composed of a lipid, a polymer, or a combination thereof. Methods of making and employing such constructs are also described herein.Type: GrantFiled: September 25, 2018Date of Patent: March 2, 2021Assignee: National Technology & Engineering Solutions of Sandia, LLCInventors: Darryl Y. Sasaki, Oscar Negrete, Edwin A. Saada, Patrick F. Fleig, Scott Reed, Eric L. Qiao
-
Patent number: 10927383Abstract: In certain aspects, the disclosure relates to compositions comprising modified Cas9 polyribonucleotides and methods of use, as well as Cas9 polynucleotides and polyribonucleotides.Type: GrantFiled: June 30, 2017Date of Patent: February 23, 2021Assignee: ethris GmbHInventors: Manish Kumar Aneja, Rebekka Kubisch-Dohmen, Christian Plank, Carsten Rudolph
-
Patent number: 10927418Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.Type: GrantFiled: November 10, 2016Date of Patent: February 23, 2021Assignees: Celator Pharmaceuticals, Inc., Oreoon Health & Science UniversityInventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer
-
Patent number: 10925831Abstract: This invention relates to use of a platinum-acridine liposomal formulation and uses thereof in treating cancer in a subject.Type: GrantFiled: August 28, 2018Date of Patent: February 23, 2021Assignee: Wake Forest UniversityInventors: Ulrich Bierbach, Song Ding, Christopher L. Hackett
-
Patent number: 10918701Abstract: The present disclosure provides a delivery system comprising (i) a physiologically acceptable carrier and (ii) a proteolytic enzyme or effector thereof for use in a method for relaxing fibers within a subject's oral cavity. In some embodiments, the relaxation is for use in tooth manipulation (particularly repositioning). In some embodiments, the method involves the use of the proteolytic enzyme or effector thereof at a concentration effective to cause relaxation of fibers between the tooth's alveolar bone and gingiva while maintaining integrity of the fibers surrounding the tooth. Also disclosed herein are methods for fiber relaxation and/or repositioning of tooth making use of the proteolytic enzyme or effector thereof.Type: GrantFiled: January 20, 2019Date of Patent: February 16, 2021Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITEDInventors: Avraham D. Schroeder, Assaf Yosef Zinger, Avishay Herman
-
Patent number: 10918598Abstract: Disclosed is a water-in-oil-in-water (W/O/W) double emulsion including a first water phase, an oil phase and a second water phase, wherein the W/O/W double emulsion is disposed in an isotonic solution, and related methods of making the W/O/W double emulsion. Also disclosed is a method of making an artificial antigen presenting cell including: providing a W/O/W double emulsion that is stored in an isotonic solution, wherein the W/O/W double emulsion includes a peptide associated with a Major Histocompatibility (pMHC) complex or a glycolipid antigen associated with a CD1d molecule, and a costimulatory molecule; and transferring the W/O/W double emulsion to an electrolyte solution, wherein the double emulsion undergoes a morphological transformation to become the artificial antigen presenting cell. Also disclosed is a method of drug delivery including administering to a subject a unilamellar vesicle containing the drug.Type: GrantFiled: December 9, 2015Date of Patent: February 16, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Abraham P. Lee, Derek Vellejo, Crystal Rapier
-
Patent number: 10912838Abstract: The present invention provides a vesicle, a conjugate, a composition comprising the vesicle or the conjugate, for use in delivering a drug to the brain, and a method for administering the same. The composition of the present invention is a composition for administration to a subject according to a dosing regimen, comprising a carrier for drug delivery, wherein the dosing regimen comprises administering the composition to a subject who has been fasted or caused to have hypoglycemia and inducing an increase in blood glucose level in the subject, and the carrier is modified at the outer surface thereof with a GLUT1 ligand.Type: GrantFiled: February 22, 2018Date of Patent: February 9, 2021Assignees: THE UNIVERSITY OF TOKYO, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITYInventors: Kazunori Kataoka, Yasutaka Anraku, Nobuhiro Nishiyama, Kanjiro Miyata, Takehiko Ishii, Yu Matsumoto, Yu Fukusato, Akihiro Mizoguchi, Takanori Yokota, Hiroya Kuwahara, Kazutaka Nishina, Hidehiro Mizusawa
-
Patent number: 10912834Abstract: Compositions containing a complex that contains a cation with alkyl chains and a macromolecule anion, and methods of making and using are disclosed. The compositions are typically charge neutral and a liquid at room temperature and standard pressure. The macromolecule anions may be nucleic acids, peptides, proteins, and/or carbohydrates. The compositions have enhanced penetration across the skin barrier (stratum corneum) and into the skin cells, delivering the macromolecules to the skin cells. The compositions are topically applied to the skin and are particularly useful for treatment of skin conditions.Type: GrantFiled: August 29, 2017Date of Patent: February 9, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Michael Zakrewsky, Samir Mitragotri
-
Patent number: 10905657Abstract: The invention relates to a solid dispersion comprising Coenzyme Q10 and a phospholipid, in the presence of a cellulosic derivative and/or a polymeric material selected from the group consisting of polyvinylpyrrolidone, polyvinyl acetate, poly (methacrylic acid, methyl methacrylate), poloxamers, chitosan, alginates, hyaluronic acid, pectin, pullulan, cyclodextrins, starch polymers, D-alpha-tocopheryl polyethylene glycol 1000 succinate.Type: GrantFiled: June 10, 2016Date of Patent: February 2, 2021Assignee: Indena S.P.A.Inventors: Daniele Ciceri, Federico Peterlongo, Massimo Ronchi
-
Patent number: 10905738Abstract: Synthetic peptides that are modulators of smooth muscle tone and compositions thereof, including pharmaceutical compositions containing a peptide, make it possible to treat indications in those in need of modulation of the smooth muscle tone, including, for example, benign prostate hyperplasia (BPH), Raynaud's syndrome, Pulmonary Arterial hypertension (PAH), systemic arterial hypertension (SAH) and hyper-reactivity of airways associated with asthma, COPD, pulmonary fibrosis, silicosis, allergic bronchopulmonary aspergillosis, hereditary angioedema, and neonatal hypoxemic respiratory failure. Although makeable in other ways, the synthetic peptides are makeable by recombinant methods or synthetic pathways.Type: GrantFiled: July 3, 2019Date of Patent: February 2, 2021Assignee: Biozeus Desenvolvimento De Produtos BiofarmacĂȘuticosInventors: Caio Victor Machado França do Nascimento, Diego Allonso Rodrigues dos Santos da Silva, Perla Villani Borges da Silva, Maria Elena De Lima Perez Garcia, Carolina Nunes da Silva, Adriano Monteiro de Castro Pimenta, Marcella Nunes de Melo Braga, Paulo Gustavo Sampaio Lacativa, Iron Francisco de Paula Junior, Gerhard Max Gross
-
Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
Patent number: 10905661Abstract: This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion.Type: GrantFiled: April 12, 2019Date of Patent: February 2, 2021Assignee: Cantex Pharmaceuticals, Inc.Inventor: Stephen Marcus -
Patent number: 10898582Abstract: Disclosed herein, is a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains, and one or more therapeutic agents, wherein the therapeutic agent is allosterically bound to the biological binding domain. Also described herein, are methods of incorporating a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains that captures the therapeutic agent without the formation of a chemical bond, and one or more therapeutic agents; physiologically acceptable compositions including them; and methods of administering the bi-functional allosteric protein-drug molecule to patients for the treatment of cancer.Type: GrantFiled: December 11, 2015Date of Patent: January 26, 2021Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Youngwook Won, David A. Bull, Kwangsuk Lim